Roche yields to cancer biosim competition by offering 'relevant' discounts: report

Biosimilars have obviously hurt Roche, so much so that the Swiss pharma is now trying to compete on prices by offering up discounts to doctors.

That’s the message Bernstein analyst Ronny Gal gleaned from perusing average sales prices published by the Centers for Medicare and Medicaid Services. This buy-and-bill market constitutes about 30% of U.S. pharma.